Catalog No.S1197 Synonyms: MK-906

For research use only.

Finasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with Ki of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).

Finasteride Chemical Structure

CAS No. 98319-26-7

Selleck's Finasteride has been cited by 5 Publications

Purity & Quality Control

Choose Selective 5-alpha Reductase Inhibitors

Other 5-alpha Reductase Products

Biological Activity

Description Finasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with Ki of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).
5-α reductase [1]
10.2 nM(Ki)
In vitro

Finasteride binds to the type 2 isozyme-NADPH complex to form a ternary complex with Ki of 1.19 nM, which then rearranges to a high affinity complex (E:I) with a pseudo first order rate constant of 1.62 ms. [1] Finasteride dose-dependently inhibits the growth rate of the LnCap cell line. [2] Finasteride markedly inhibits prostate-specific antigen (PSA) secretion and expression in LNCaP cells. [3]

In vivo Finasteride induces dosage-related incidences of hypospadias (penischisis) in male offspring with a threshold dosage level near 0.1 mg/kg/day and a 100% effect level of 100 mg/kg/day in male rats. Finasteride also causes decreased anogenital distance in male offspring in male rats. [4] Finasteride and castration decreases prostate weight at day 21 by 65% and 93%, respectively, in rats. Finasteride has no significant effect on DNA content after 4 days and decreases DNA content by a maximum of 52% at 14 days in rats. Finasteride causes a less intense increase in staining in which 16% of epithelial cells stained for tissue transglutaminase on day 9 with a return to baseline by day 14 in rats. Finasteride-induced staining is less intense with peak staining at day 4 (0.7% of epithelial cells) and a return to control values by day 9 in rats. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 372.54


CAS No. 98319-26-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04288427 Recruiting Drug: Finasteride Benign Prostatic Hyperplasia|Prostate Hyperplasia|Prostate Disease|Prostate Hypertrophy|Prostate Pain|Lower Urinary Tract Symptoms|Urinary Obstruction|Urinary Tract Disease Beth Israel Deaconess Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) September 25 2020 Not Applicable
NCT03669692 Withdrawn Behavioral: Caloric Restriction|Behavioral: Control Prostatic Hyperplasia Benign|Metabolic Syndrome Complexo Hospitalario Universitario de A Coruña July 10 2018 Not Applicable
NCT02824380 Completed Drug: DA-4001 H|Drug: DA-4001 L Androgenic Alopecia Dong-A ST Co. Ltd. July 2016 Phase 1
NCT02146937 Withdrawn Drug: Bicalutamide plus Finasteride- Combination therapy Detectable Prostate Nodules Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins March 2014 Phase 2
NCT01703520 Completed -- Male Breast Cancer Organon and Co|Institute for Applied Economics and Health Research Aps May 1 2011 --

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Finasteride | Finasteride supplier | purchase Finasteride | Finasteride cost | Finasteride manufacturer | order Finasteride | Finasteride distributor